Lupin Limited
LUPIN · Pharma · NSE
₹2,293
Current Market Price
Fair Value (DCF)
₹2,755
Discount to FV
+20.1%
Updated just now
YieldIQ Score
52/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
52%
ROE
23.8%
Debt/Equity
0.29
WACC
9.8%
Market Cap
₹1.05 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
29.9%
Return on capital employed
EV / EBITDA
12.5×
Enterprise multiple
Debt / EBITDA
0.9×
Leverage vs earnings
Interest Coverage
16.8×
EBIT covers interest
Current Ratio
1.90×
Short-term liquidity
Asset Turnover
0.73×
Revenue per ₹ of assets
Revenue CAGR (3Y)
10.1%
3-year revenue growth
Revenue CAGR (5Y)
10.1%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,293.3
Bear case
Margin of Safety -64.3%
Implied upside -39.1%
Base case
Margin of Safety +14.3%
Implied upside +16.7%
Bull case
Margin of Safety +28.1%
Implied upside +39.0%
Ratio Trends
LUPIN · last 9 annual periods
ROE
23.8%
ROCE
29.9%
Operating Margin
—
Debt / Equity
0.29×
PE
19.8×
EV / EBITDA
12.5×
Historical Financials
LUPIN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹16.2K Cr | ₹16.3K Cr | ₹19.7K Cr | ₹22.2K Cr | ₹27.5K Cr | +14.1% |
| EBITDA | ₹394 Cr | ₹1837 Cr | ₹3898 Cr | ₹5479 Cr | ₹8683 Cr | +116.7% |
| EBIT | ₹-1230 Cr | ₹991 Cr | ₹2734 Cr | — | — | — |
| PAT | ₹-1528 Cr | ₹430 Cr | ₹1914 Cr | ₹3282 Cr | ₹5333 Cr | — |
| EPS (diluted) | ₹-33.65 | ₹9.41 | ₹41.87 | — | — | — |
| CFO | ₹367 Cr | ₹1897 Cr | ₹3648 Cr | ₹3000 Cr | ₹7335 Cr | +111.4% |
| CapEx | ₹-905 Cr | ₹-1500 Cr | ₹-929 Cr | ₹-1682 Cr | ₹-2055 Cr | — |
| FCF | ₹-538 Cr | ₹398 Cr | ₹2719 Cr | ₹1318 Cr | ₹5280 Cr | — |
| Total Assets | ₹21.8K Cr | ₹23.0K Cr | ₹24.0K Cr | ₹29.2K Cr | ₹38.4K Cr | +15.1% |
| Total Debt | ₹4158 Cr | ₹4542 Cr | ₹2922 Cr | ₹5448 Cr | ₹6616 Cr | +12.3% |
| Shareholders' Equity | ₹12.2K Cr | ₹12.5K Cr | ₹14.3K Cr | ₹17.2K Cr | ₹22.4K Cr | +16.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
LUPIN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 DRREDDY DRREDDY | — | — | Pending | 11.4% | 24.4× |
 CIPLA Cipla Limited | -14.0%-12.3% upside | 45 | Near Fair Value | 11.3% | 25.5× |
 ZYDUSLIFE ZYDUSLIFE | — | — | Pending | 17.2% | — |
 MANKIND MANKIND | — | — | Pending | 11.7% | — |
 TORNTPHARM Torrent Pharmaceuticals Limited | -171.7%-63.2% upside | 40 | Above Fair Value | 25.8% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹34.50/sh
Last payout
2025-07-25
₹12.00
Peak payout
₹12.00
Trailing yield
0.52%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Lupin Limited (LUPIN.NS) trades at 2293.30 vs a model fair value of 2754.71, a gap of 20.1%. Piotroski F-score: 6/9. Moat label: Moderate...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of LUPIN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for LUPIN →
Compare
Head-to-head with peers
Compare LUPIN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse LUPINNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.